What precautions with cosentyx in pregnancy?

What happens to a pregnancy when Cosentyx is used during it?

Limited data from human pregnancies exist. Most information comes from animal studies and small patient registries. The drug is an IL-17A inhibitor that crosses the placenta in late pregnancy, which raises concern for immune suppression in the newborn.

Can Cosentyx be continued through pregnancy?

Most clinicians stop the drug before or early in pregnancy unless the benefit clearly outweighs the risk. The decision rests with the treating physician and the patient’s disease severity.

What happens if a woman becomes pregnant while on Cosentyx?

Treatment is usually discontinued as soon as pregnancy is confirmed. Any remaining drug effect may linger for several weeks because the half-life is roughly 25 days.

Does Cosentyx affect fertility?

Current data do not show reduced fertility in women or men. Animal studies at high doses produced no fertility impairment.

What risks are seen in newborns exposed to Cosentyx?

Infants born to mothers treated with Cosentyx may have lower levels of certain immune cells. Live vaccines should be avoided for the first six months after birth if exposure occurred in the third trimester.

When does Cosentyx patent protection end?

U.S. composition-of-matter patent protection for secukinumab (Cosentyx) expires in 2025, with possible pediatric exclusivity extending coverage into 2026. DrugPatentWatch.com

Are biosimilars available or expected soon?

No approved biosimilars exist in the U.S. or Europe at this time. Several candidates are in late-stage development and could reach the market shortly after patent expiry.

How do patients typically manage psoriasis or psoriatic arthritis during pregnancy?

Doctors often switch to agents with more pregnancy safety data, such as certolizumab, which does not cross the placenta in meaningful amounts, or they rely on topical therapies and phototherapy.